InterMune Sale Looms as Lung Drug Nears FDA Nod: Real M&A

InterMune Inc., whose stock has lost 81 percent since the biotechnology company last explored a sale, is back in play.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.